Close

BofA/Merrill Lynch Downgrades Pacira Pharmaceuticals (PCRX) to Underperform

February 26, 2015 6:19 AM EST
Get Alerts PCRX Hot Sheet
Price: $29.29 --0%

Rating Summary:
    16 Buy, 11 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 5 | New: 36
Join SI Premium – FREE

BofA/Merrill Lynch downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Neutral to Underperform with a price target of $110.00 (from $112.00).

Analyst Steve Byrne said high expectations are priced in, with more potential to miss than to exceed views.

The firm lowered FY 2015 EPS from $2.53 to $2.14 and FY 2016 EPS from $6.43 to $5.70.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $119.27 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, Downgrades, Hot Downgrades